A single-ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration of a MEK inhibitor, CH4987655 (R04987655), in healthy volunteers: implications of clinical activity using a biological marker.

被引：0
|
作者：
Lee, Lucy
Niu, Huifeng
Rueger, Ruediger
Igawa, Yuriko
Deutsch, Jonathan
Ishii, Nobuya
Mu, Song
Sakamoto, Yuuichiro
Gimmi, Claude
Weissgerber, Georges
机构：
[1] Roche Pharmaceut, Nutley, NJ USA
[2] Roche Diagnost, Penzberg, Germany
[3] Chugai Pharmaceut, Tokyo, Japan
[4] Roche Pharmaceut, Basel, Switzerland
[5] Roche Clin Pharmacol Unit, Strasbourg, France
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3589
引用
收藏
页数：2
相关论文
共 6 条
  • [1] A single-ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration of a MEK inhibitor, CH4987655 (RO4987655), in healthy volunteers: implications of clinical activity using a biological marker.
    Lee, Lucy
    Niu, Huifeng
    Rueger, Ruediger
    Igawa, Yuriko
    Deutsch, Jonathan
    Ishii, Nobuya
    Mu, Song
    Sakamoto, Yuuichiro
    Gimmi, Claude
    Weissgerber, Georges
    CANCER RESEARCH, 2009, 69
  • [2] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
    Lee, Lucy
    Niu, Huifeng
    Rueger, Ruediger
    Igawa, Yuriko
    Deutsch, Jonathan
    Ishii, Nobuya
    Mu, Song
    Sakamoto, Yuuichiro
    Busse-Reid, Rachel
    Gimmi, Claude
    Goelzer, Petra
    De Schepper, Stefanie
    Yoshimura, Yashushi
    Barrett, Joanne
    Ishikawa, Yuji
    Weissgerber, Georges
    Peck, Richard
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7368 - 7374
  • [3] Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers
    Schmitt, Christophe
    Pannier, Anne
    McIntyre, Christine
    Zandt, Hagen
    Ciorciaro, Cornelia
    Winters, Katie
    Pepper, Tom
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 499 - 510
  • [4] Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
    Moreno, Ofir
    Butler, Todd
    Zann, Vanessa
    Willson, Ashley
    Leung, Pui
    Connor, Alyson
    CLINICAL THERAPEUTICS, 2018, 40 (11) : 1855 - 1867
  • [5] Clinical pharmacokinetics and pharmacodynamics of ME-401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ, following single ascending dose administration to healthy volunteers
    Moreno, Ofir
    Imani, Robert
    Zann, Vanessa
    Leung, Pui
    CANCER RESEARCH, 2016, 76
  • [6] Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study
    Wang, Yuhao
    Yu, Chao
    Hu, Mengyue
    Wang, Lu
    Chen, Meixia
    Liu, Hanmo
    Wu, Nan
    Hou, Jie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
1